- Home
- SNSE vs BIAF Comparison
SNSE vs BIAF Comparison
Compare SNSE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- BIAF
- Stock Information
- Founded
- SNSE 2005
- BIAF 2014
- Country
- SNSE United States
- BIAF United States
- Employees
- SNSE N/A
- BIAF N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SNSE Health Care
- BIAF Health Care
- Exchange
- SNSE Nasdaq
- BIAF Nasdaq
- Market Cap
- SNSE 12.5M
- BIAF 12.2M
- IPO Year
- SNSE 2021
- BIAF 2022
- Fundamental
- Price
- SNSE $0.33
- BIAF $0.70
- Analyst Decision
- SNSE Strong Buy
- BIAF Hold
- Analyst Count
- SNSE 4
- BIAF 1
- Target Price
- SNSE $4.25
- BIAF N/A
- AVG Volume (30 Days)
- SNSE 8.2M
- BIAF 28.4M
- Earning Date
- SNSE 03-28-2025
- BIAF 05-14-2025
- Dividend Yield
- SNSE N/A
- BIAF N/A
- EPS Growth
- SNSE N/A
- BIAF N/A
- EPS
- SNSE N/A
- BIAF N/A
- Revenue
- SNSE N/A
- BIAF $9,362,022.00
- Revenue This Year
- SNSE N/A
- BIAF $25.19
- Revenue Next Year
- SNSE N/A
- BIAF $20.00
- P/E Ratio
- SNSE N/A
- BIAF N/A
- Revenue Growth
- SNSE N/A
- BIAF 269.68
- 52 Week Low
- SNSE $0.25
- BIAF $0.24
- 52 Week High
- SNSE $1.94
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- SNSE 34.62
- BIAF 58.28
- Support Level
- SNSE $0.25
- BIAF $0.24
- Resistance Level
- SNSE $0.76
- BIAF $1.55
- Average True Range (ATR)
- SNSE 0.07
- BIAF 0.13
- MACD
- SNSE -0.01
- BIAF 0.08
- Stochastic Oscillator
- SNSE 14.76
- BIAF 35.17
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.